

**DRAFT
TOXICOLOGICAL PROFILE FOR
PERCHLORATES**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2005

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Toxicology Information Branch
1600 Clifton Road NE
Mailstop F-32
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.


The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road NE
Mail Stop F-32
Atlanta, Georgia 30333

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 7, 2003 (68 FR 63098). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); and October 25, 2001 (66 FR 54014). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

A handwritten signature in black ink, reading "Julie Louise Gerberding". The signature is written in a cursive style with a large initial "J".

Julie Louise Gerberding, M.D., M.P.H.

Administrator

Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone:	1-888-42-ATSDR or (404) 498-0110	Fax:	(770) 488-4178
E-mail:	atsdric@cdc.gov	Internet:	http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental*

Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sharon Wilbur, M.A.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Gary Diamond, Ph.D.
Fernando Lladós, Ph.D.
Marc Odin, M.S., D.A.B.T.
Daniel Plewak, B.S.
Jay Tunkel, Ph.D.
Syracuse Research Corporation, Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

PEER REVIEW

A peer review panel was assembled for perchlorates. The panel consisted of the following members:

1. Dr. Kannan Krishnan, Professor of Occupational and Environmental Health, University of Montreal, Montreal PQ, Canada;
2. Dr. Thomas Zoeller, Professor of Biology, University of Massachusetts, Amherst, MA; and
3. Dr. Gary Williams, Professor of Pathology, Department of Pathology, New York Medical College, Valhalla, NY.

These experts collectively have knowledge of perchlorates' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

In addition, the National Academy of Sciences has provided a report on the science issues related to human perchlorate exposure. This review can be found at <http://books.nap.edu/catalog/11202.html>. The NAS was provided a draft of the ATSDR toxicological profile, which they considered while conducting their evaluation.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS.....	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT.....	1
1.1 WHAT ARE PERCHLORATES?.....	1
1.2 WHAT HAPPENS TO PERCHLORATES WHEN THEY ENTER THE ENVIRONMENT?	3
1.3 HOW MIGHT I BE EXPOSED TO PERCHLORATES?.....	4
1.4 HOW CAN PERCHLORATES ENTER AND LEAVE MY BODY?.....	5
1.5 HOW CAN PERCHLORATES AFFECT MY HEALTH?.....	6
1.6 HOW CAN PERCHLORATES AFFECT CHILDREN?.....	7
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PERCHLORATES?.....	8
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO PERCHLORATES?.....	9
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?.....	10
1.10 WHERE CAN I GET MORE INFORMATION?	11
2. RELEVANCE TO PUBLIC HEALTH	13
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PERCHLORATES IN THE UNITED STATES	13
2.2 SUMMARY OF HEALTH EFFECTS	15
2.3 MINIMAL RISK LEVELS	19
3. HEALTH EFFECTS	23
3.1 INTRODUCTION	23
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE.....	24
3.2.1 Inhalation Exposure	25
3.2.1.1 Death	25
3.2.1.2 Systemic Effects.....	25
3.2.1.3 Immunological and Lymphoreticular Effects	29
3.2.1.4 Neurological Effects	29
3.2.1.5 Reproductive Effects.....	29
3.2.1.6 Developmental Effects.....	29
3.2.1.7 Cancer	29
3.2.2 Oral Exposure.....	29
3.2.2.1 Death	29
3.2.2.2 Systemic Effects.....	30
3.2.2.3 Immunological and Lymphoreticular Effects	57
3.2.2.4 Neurological Effects	58
3.2.2.5 Reproductive Effects.....	59

3.2.2.6	Developmental Effects	60
3.2.2.7	Cancer	69
3.2.3	Dermal Exposure.....	70
3.2.3.1	Death.....	70
3.2.3.2	Systemic Effects.....	70
3.2.3.3	Immunological and Lymphoreticular Effects	70
3.2.3.4	Neurological Effects	70
3.2.3.5	Reproductive Effects.....	70
3.2.3.6	Developmental Effects.....	71
3.2.3.7	Cancer	71
3.3	GENOTOXICITY	71
3.4	TOXICOKINETICS	71
3.4.1	Absorption.....	72
3.4.1.1	Inhalation Exposure	72
3.4.1.2	Oral Exposure	72
3.4.1.3	Dermal Exposure	73
3.4.2	Distribution	73
3.4.2.1	Inhalation Exposure	73
3.4.2.2	Oral Exposure	74
3.4.2.3	Dermal Exposure	74
3.4.2.4	Other Routes of Exposure.....	74
3.4.3	Metabolism.....	75
3.4.4	Elimination and Excretion.....	75
3.4.4.1	Inhalation Exposure	75
3.4.4.2	Oral Exposure	76
3.4.4.3	Dermal Exposure	76
3.4.4.4	Other Routes of Exposure.....	77
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	77
3.5	MECHANISMS OF ACTION.....	86
3.5.1	Pharmacokinetic Mechanisms.....	86
3.5.2	Mechanisms of Toxicity.....	87
3.5.3	Animal-to-Human Extrapolations	97
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	102
3.7	CHILDREN'S SUSCEPTIBILITY	103
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	106
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Perchlorates	107
3.8.2	Biomarkers Used to Characterize Effects Caused by Perchlorates	108
3.9	INTERACTIONS WITH OTHER CHEMICALS.....	108
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	109
3.11	METHODS FOR REDUCING TOXIC EFFECTS	110
3.11.1	Reducing Peak Absorption Following Exposure.....	110
3.11.2	Reducing Body Burden	110
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	110
3.12	ADEQUACY OF THE DATABASE.....	111
3.12.1	Existing Information on Health Effects of Perchlorates	111
3.12.2	Identification of Data Needs.....	113
3.12.3	Ongoing Studies	120
4.	CHEMICAL AND PHYSICAL INFORMATION.....	123
4.1	CHEMICAL IDENTITY	123
4.2	PHYSICAL AND CHEMICAL PROPERTIES	123

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	127
5.1 PRODUCTION.....	127
5.2 IMPORT/EXPORT.....	130
5.3 USE.....	130
5.4 DISPOSAL	134
6. POTENTIAL FOR HUMAN EXPOSURE	137
6.1 OVERVIEW	137
6.2 RELEASES TO THE ENVIRONMENT	141
6.2.1 Air	142
6.2.2 Water.....	143
6.2.3 Soil	144
6.3 ENVIRONMENTAL FATE.....	145
6.3.1 Transport and Partitioning.....	146
6.3.2 Transformation and Degradation	148
6.3.2.1 Air	148
6.3.2.2 Water.....	148
6.3.2.3 Sediment and Soil	150
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	151
6.4.1 Air	151
6.4.2 Water.....	152
6.4.3 Sediment and Soil	154
6.4.4 Other Environmental Media.....	155
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	157
6.6 EXPOSURES OF CHILDREN	159
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	160
6.8 ADEQUACY OF THE DATABASE.....	160
6.8.1 Identification of Data Needs	161
6.8.2 Ongoing Studies	166
7. ANALYTICAL METHODS	169
7.1 BIOLOGICAL MATERIALS	170
7.2 ENVIRONMENTAL SAMPLES.....	170
7.3 ADEQUACY OF THE DATABASE.....	171
7.3.1 Identification of Data Needs	172
7.3.2 Ongoing Studies	172
8. REGULATIONS AND ADVISORIES	173
9. REFERENCES	177
10. GLOSSARY	221

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETSA-1

B. USER'S GUIDEB-1

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....C-1

D. INDEXD-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Perchlorates – Inhalation.....	27
3-2. Levels of Significant Exposure to Perchlorates – Oral.....	42
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	79
3-4. Structure of AFRL PBPK Model of Perchlorate in Adult Male Humans and Rats.....	83
3-5. Pathways Uptake and Metabolism of Iodide in the Thyroid Gland.....	89
3-6. Hypothalamic-pituitary-thyroid (HPT) Feedback Pathways for Regulation of Thyroid Hormone Production and Secretion.....	90
3-7. Comparison of Dose-Response Relationships for the Inhibitory Effect of Perchlorate on 24-hour Thyroid Iodide Uptake in Humans and Rats.....	99
3-8. Changes in Serum Thyroid Hormone Levels in Rats Exposed to Perchlorate in Drinking Water for 14 Days.....	101
3-9. Existing Information on Health Effects of Perchlorate	112
6-1. Frequency of NPL Sites with Perchlorate Contamination.....	138

LIST OF TABLES

3-1. Levels of Significant Exposure to Perchlorates – Inhalation.....	26
3-2. Levels of Significant Exposure to Perchlorates – Oral.....	31
3-3. Perchlorate and Iodide Parameter Values for the AFRL Adult Male Rat and Human PBPK Models	81
3-4. Typical Reference Ranges for Serum Thyroid Hormones and TSH in Humans.....	94
4-1. Chemical Identity of Perchlorates	124
4-2. Physical and Chemical Properties of Perchlorates	125
5-1. U.S. Manufacturers of Perchlorates.....	129
6-1. Ongoing Studies on the Potential for Human Exposure to Perchlorates (Including Studies on Fate and Occurrence).....	167
8-1. Regulations and Guidelines Applicable to Perchlorates.....	174